MAP4K4

Across TCGA pan-cancer cohorts, MAP4K4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAP4K4 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher MAP4K4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP4K4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

SCLC, BRCA, and UCEC are the cancer types where MAP4K4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
BRCA	OS	Median	III,IV	0.233	0.833	.001	12	view →
UCEC	DFS	Median	All	0.922	0.617	.022	8	view →
BLCA	OS	Median	II,III,IV	1.000	0.411	.038	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAP4K4–SCLC (OS)

Open the SCLC breakdown →